Zenas Biopharma Inc. Faces Multiple Class Action Lawsuits Amid Financial Turmoil
In a turbulent week for Zenas Biopharma Inc., a series of class action lawsuits have been filed against the company, raising concerns among investors and shaking confidence in the biopharma sector. Zenas, a health care company listed on Nasdaq under the ticker ZBIO, has seen its stock price plummet from a 52-week high of $26.25 in October 2024 to a close of $9.61 on June 4, 2025. The company’s market capitalization stands at $479 million, with a negative price-to-earnings ratio of -0.945646, reflecting the financial challenges it faces.
Investor Alert: Multiple Law Firms Announce Lawsuits
On June 7, 2025, Pomerantz LLP announced a class action lawsuit against Zenas Biopharma, alleging securities fraud and other unlawful business practices. Investors who have suffered losses are urged to contact Danielle Peyton at Pomerantz to discuss their rights and the possibility of becoming the lead plaintiff in the case. The deadline to ask the court for lead plaintiff status is June 16, 2025.
Similarly, the DJS Law Group and the Schall Law Firm have both filed lawsuits against Zenas, citing violations of federal securities laws. These firms claim that Zenas made false and misleading statements regarding its financial health, particularly overstating its operational runway based on IPO proceeds. Investors who purchased shares during the IPO period are encouraged to contact these firms before the June 16 deadline.
The Gross Law Firm has also issued a notice to shareholders, urging those who incurred losses to consider joining the class action. The lawsuit covers securities acquired during Zenas’s September 2024 IPO, with no requirement for lead plaintiff appointment to participate in any potential recovery.
Rosen Law Firm Targets High-Loss Investors
Adding to the legal pressure, the Rosen Law Firm has specifically targeted investors with losses exceeding $100,000, offering them the opportunity to lead the securities lawsuit. The firm emphasizes a contingency fee arrangement, meaning investors can seek compensation without upfront costs.
Investor Concerns and Next Steps
The flurry of legal actions underscores significant investor concerns about Zenas Biopharma’s financial disclosures and business practices. With multiple law firms vying for lead plaintiff status, investors are advised to act swiftly to protect their interests. Those affected are encouraged to contact the respective law firms to explore their options and understand their rights in the unfolding legal battles.
As the situation develops, Zenas Biopharma faces not only legal challenges but also the task of restoring investor confidence and stabilizing its financial standing in a highly competitive health care sector.